Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Nausea typically occurs during the first 4-8 weeks of treatment or following dose increases, with many patients experiencing gradual improvement as their body adjusts to the medication
Sources Epidemiology and Clinical Outcomes of Vasomotor Symptoms Among Perimenopausal Women in the US: a Systematic Review Prevalence and Severity of Symptoms Across the Menopause Transition: Findings from the AMY Study Global Perspectives on Perimenopause: a Digital Survey of Knowledge and Symptoms Using the Flo Application The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution Wilding JPH et al
At the highest dose of 12 mg retatrutide, the average weight loss after 48 weeks was 24.2% with reduction up to 30% from the baseline weight in 25% of participants
The Phase 2 trial indicated that retatrutide is similar in terms of safety and side effects to tirzepatide and semaglutide, and the TRIUMPH-1 Phase 3 trial confirmed a manageable safety profile at all doses tested
)
ACS Appl Mater
doi: 10.1007/s00109-016-1488-y
US$ 23.86
US$ 25.73
US$ 21.38
US$ 23.56
US$ 29.94
US$ 21.61
US$ 29.63
